November 2016

The latest from Cogstate, leaders in optimizing the measurement of cognition

Cogstate Announces New Executive Appointments For Clinical Trials And Healthcare Business Units

November 30, 2016

The cognitive science company, Cogstate Ltd (ASX.CGS) announced today two key appointments to executive positions. George Hunnewell has been named Chief Operating Officer of Cogstate and President of the Cogstate Clinical Trials division. Hunnewell, who previously served as Corporate Vice President, Clinical Research Services for Parexel International Corporation, will be responsible for the company’s worldwide […]

High Blood Pressure In Children Negatively Impacts Cognitive Performance

November 16, 2016

According to the Centers for Disease Control and Prevention, obesity among U.S. children and adolescents (aged 2-19) remained high between 2011 and 2014 at about 17%. Of these approximately 13 million young people, almost 10% are also diagnosed with primary hypertension, risking long-term cardiovascular organ damage as they move into adulthood. Beyond its physical effects, […]

Study Finds Brexpiprazole To Be An Effective Alternative To Aripiprazole

November 8, 2016

Despite the number of available antipsychotics, schizophrenia is still a complicated brain disorder to treat, in part due to the different side effects of various treatment regimens between patients. Brexpiprazole, a serotonin-dopamine activity modulator approved by the FDA for schizophrenia in 2015, was developed by Otsuka as a successor to aripiprazole, whose U.S. patent expired […]